Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-545 (Sifalimumab) in Japanese SLE Patients
NCT01031836Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2009
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sifalimumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Nov 2009; status: completed.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01031836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031836.